HNC364 vs Rasagiline (Azilect)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: MAO-B · full Parkinson's Disease pipeline

HNC364

Developed by Guangzhou Henovcom Bioscience Co. Ltd.

Phase 1 in Parkinson's Diseasesmall molecule
Weak signal

NCT05523570 · Phase 1 · completed

Participants were not randomized and neither they nor the investigators were blinded, and there was no placebo or comparator group, so this design cannot separate a real drug effect from chance, natural variation, or expectation. Results have not yet been posted.

Next expected readout: December 2026 · NCT06798519 (registry estimate)

No aligned efficacy figure on record for this race.

Rasagiline (Azilect)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT01479530 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial with 321 participants, with 158 assigned to placebo and 163 to rasagiline. The primary clinical endpoint—change in daily OFF time—favored rasagiline and was statistically significant (p=0.0228).

Reported efficacy

Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Azilect® -1.25 hours (Standard Error 0.16) vs Placebo -0.76 hours (Standard Error 0.16) (met)

Result source: NCT01479530

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHNC364Rasagiline (Azilect)
OFF time, change—Not reported-1.3 vs -0.8−0.5 vs placebowk 16 · n 158NCT01479530
1 other result
ON time without troublesome dyskinesia, change—Not reported—Not posted · NCT00203034
UPDRS Part III, change—Not reported—Not posted · NCT00203034
MDS-UPDRS Part II, change—Not reported0.1 vs 2.3−2.2 vs placebo1 mg · wk 26 · n 116NCT02337725
2 other results
  • -0.3 vs 1.0 1 mg · wk 26 · n 126 · Phase 2/3 · secondary NCT02337738
  • -0.3 vs 1.0 0.5 mg · wk 26 · n 132 · Phase 2/3 · secondary NCT02337738

OFF time, change

HNC364
—Not reported
Rasagiline (Azilect)
-1.3 vs -0.8−0.5 vs placebowk 16 · n 158NCT01479530
1 other result

ON time without troublesome dyskinesia, change

HNC364
—Not reported
Rasagiline (Azilect)
—Not posted · NCT00203034

UPDRS Part III, change

HNC364
—Not reported
Rasagiline (Azilect)
—Not posted · NCT00203034

MDS-UPDRS Part II, change

HNC364
—Not reported
Rasagiline (Azilect)
0.1 vs 2.3−2.2 vs placebo1 mg · wk 26 · n 116NCT02337725
2 other results
  • -0.3 vs 1.0 1 mg · wk 26 · n 126 · Phase 2/3 · secondary NCT02337738
  • -0.3 vs 1.0 0.5 mg · wk 26 · n 132 · Phase 2/3 · secondary NCT02337738
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HNC364: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HNC364: 0 of 4 rows · Rasagiline (Azilect): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRasagiline (Azilect)
Dropout rate
7.4%a
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
12.1%
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
27%1 mg
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
11.6%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence
15.5%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
6.8%1 mg
NCT02337725 · Phase 3 · registry result, not featured evidence
20.2%1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
22.4%0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
Discontinued due to AEs
3.7%a
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
10.6%
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
20.7%1 mg
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.1%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence
2.9%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
—1 mg
NCT02337725 · Phase 3 · registry result, not featured evidence
16.3%1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
13.4%0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
Serious AEs
4.3%a
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
7.6%
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
17.6%1 mg
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.2%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence
5.1%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
3.4%1 mg
NCT02337725 · Phase 3 · registry result, not featured evidence
7.8%1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
7.5%0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
Most frequent reported AEs
a
dyskinesia 6.7% (placebo 7.6%)
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
dyskinesia 12.1% (placebo 7.6%)
dizziness 6.1% (placebo 1.5%)
dyspnoea 6.1% (placebo 0%)
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
1 mg
fall 16.7%
nasopharyngitis 14%
dyskinesia 10.8%
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1 mg
nasopharyngitis 17.9%
fall 6.3%
contusion 5.3%
NCT02337751 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 26.5%
fall 9.4%
eczema 7.7%
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
1 mg
nasopharyngitis 15.4% (placebo 15.1%)
fall 5.1% (placebo 5.6%)
NCT02337725 · Phase 3 · registry result, not featured evidence
1 mg
dyskinesia 15.5% (placebo 7.1%)
nasopharyngitis 14.7% (placebo 9.2%)
fall 13.2% (placebo 5.7%)
NCT02337738 · Phase 2/3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 18% (placebo 9.2%)
fall 9.8% (placebo 5.7%)
dyskinesia 8.3% (placebo 7.1%)
NCT02337738 · Phase 2/3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Rasagiline (Azilect)

OFF Time -1.25 vs -0.76 placebo hours @ 16wk
absolute change · hours
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
-1.59 vs -1.24 placebo hours
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
CGI-I 3.15 vs 3.56 placebo score @ 16wk
absolute value · score
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
3.05 vs 3.35 placebo score @ 18wk
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
UPDRS-ADL -2.21 vs -1.2 placebo score @ 16wk
absolute change · score
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
-0.57 vs 0.13 placebo score @ 18wk
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
UPDRS Motor -3.34 vs -1.75 placebo score @ 16wk
absolute change · score
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
-2.87 vs -1.52 placebo score @ 18wk
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
MDS-UPDRS Part II 0 score @ 52wk1 mg
absolute change · score
No placebo or comparator arm
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III -7.6 score @ 52wk1 mg
absolute change · score
No placebo or comparator arm
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.89 hours @ 52wk1 mg
absolute change · hours
No placebo or comparator arm
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Parts II III -2.8 score @ 52wk1 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT02337751 · Phase 3 · registry result, not featured evidence
show 1 more result
-2.8 score @ 52wk1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
MDS-UPDRS Parts II III -4.52 vs 1.87 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
MDS-UPDRS Part I 0.18 vs 0.98 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
MDS-UPDRS Part II 0.13 vs 2.32 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
show 2 more results
-0.3 vs 0.97 placebo score @ 26wk1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
-0.3 vs 0.97 placebo score @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
MDS-UPDRS Part III -4.47 vs -0.48 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
show 2 more results
-5.65 vs -3.5 placebo score @ 26wk1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
-5.24 vs -3.5 placebo score @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HNC364's landscape · Rasagiline (Azilect)'s landscape